Malignant neoplasm of breast
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
Out of 17 genes investigated, 15 were found to be significantly associated with the risk of cancer: four genes were shared by all three malignancies (ARNTL, CLOCK, RORA and RORB), two by breast and lung cancer (CRY1 and CRY2) and three by prostate and lung cancer (NPAS2, NR1D1 and PER3), whereas four genes were specific for lung cancer (ARNTL2, CSNK1E, NR1D2 and PER2) and two for breast cancer (PER1, RORC).
|
29455641 |
2018 |
Malignant neoplasm of breast
|
0.360 |
Biomarker
|
disease |
BEFREE |
There was some evidence of an interaction between PER1 and nightwork in breast cancer in the whole sample (P=0.024), although the effect was not statistically significant after correcting for multiple testing (P=0.452).
|
24919398 |
2014 |
Malignant neoplasm of breast
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
Following permutation analysis, two SNPs (rs3816360 in ARNTL and rs11113179 in CRY1) displayed significant associations with breast cancer and one SNP (rs3027188 in PER1) was marginally significant; however, none were significant following adjustment for the false discovery rate.
|
23725643 |
2013 |
Malignant neoplasm of breast
|
0.360 |
Biomarker
|
disease |
BEFREE |
In the first genome-wide DNA methylation profiling according to the receptor status of breast cancer, we found that ER/PR status affects the DNA methylation state of FAM124B, ST6GALNAC1, NAV1 and PER1 in breast cancer.
|
20724461 |
2010 |
Malignant neoplasm of breast
|
0.360 |
Biomarker
|
disease |
BEFREE |
Because Per1, another key clock gene, is mutated in human breast cancers, and because its clock functions are similar and complementary to those of Per2, we have studied its role in modulating breast cancer cell proliferation and tumor growth.
|
19916834 |
2009 |
Malignant neoplasm of breast
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers.
|
15790588 |
2005 |
Malignant neoplasm of breast
|
0.360 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Colorectal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
By using RT-quantitative PCR, tissue microarray (TMA) and immunohistochemistry, we detected mRNA levels and protein levels of PER1 and ER2 in the cancerous tissues and paired normal adjacent tissues in patients with colorectal cancer.
|
26339386 |
2015 |
Colorectal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Significantly poorer survival rates were evidenced for CRC patients with lower expression in the tumor tissue of PER1 (p=.010), PER3 (p= .010), and CSNKIE (p=.024).
|
22080729 |
2011 |
Colorectal Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer.
|
19148895 |
2009 |
Colorectal Carcinoma
|
0.330 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Autistic Disorder
|
0.310 |
Biomarker
|
disease |
CTD_human |
Association of Per1 and Npas2 with autistic disorder: support for the clock genes/social timing hypothesis.
|
17264841 |
2007 |
Autistic Disorder
|
0.310 |
Biomarker
|
disease |
BEFREE |
Association of Per1 and Npas2 with autistic disorder: support for the clock genes/social timing hypothesis.
|
17264841 |
2007 |
Cocaine Dependence
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
Human clock, PER1 and PER2 polymorphisms: lack of association with cocaine dependence susceptibility and cocaine-induced paranoia.
|
17106427 |
2006 |
Substance Withdrawal Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
Circadian alteration in neurobiology during protracted opiate withdrawal in rats.
|
20738730 |
2010 |
Drug Withdrawal Symptoms
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Circadian alteration in neurobiology during protracted opiate withdrawal in rats.
|
20738730 |
2010 |
Withdrawal Symptoms
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Circadian alteration in neurobiology during protracted opiate withdrawal in rats.
|
20738730 |
2010 |
Juvenile-Onset Still Disease
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets.
|
19565504 |
2009 |
Juvenile arthritis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets.
|
19565504 |
2009 |
Juvenile psoriatic arthritis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets.
|
19565504 |
2009 |
Polyarthritis, Juvenile, Rheumatoid Factor Negative
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets.
|
19565504 |
2009 |
Polyarthritis, Juvenile, Rheumatoid Factor Positive
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets.
|
19565504 |
2009 |
Myeloid Leukemia, Chronic
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression levels of hPER1, hPER2, hPER3, hCRY1, hCRY2 and hBMAL1 were significantly impaired in both chronic phase and blastic crisis of CML cases compared with those in healthy individuals (P < 0.001).
|
16999817 |
2006 |
Attention Deficit Disorder
|
0.200 |
Biomarker
|
disease |
MGD |
Circadian modulation of dopamine levels and dopaminergic neuron development contributes to attention deficiency and hyperactive behavior.
|
25673850 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Per1/2<sup>-/-</sup> mice also exhibited a more robust immune response and slower tumor growth rate, indicating that the circadian clock also influences the immune response to melanoma tumors.
|
29581861 |
2018 |